Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?

被引：20

作者：

Bomback, Andrew S. ^{[1
]}

Kshirsagar, Abhijit V. ^{[1
]}

Klemmer, Philip J. ^{[1
]}

机构：

[1] Univ N Carolina, Dept Med, Div Nephrol & Hypertens, Chapel Hill, NC USA

来源：

NATURE CLINICAL PRACTICE NEPHROLOGY | 2009年 / 5卷 / 02期

关键词：

CHRONIC CYCLOSPORINE NEPHROTOXICITY; PLASMA-ALDOSTERONE; METABOLIC SYNDROME; BLOCKADE;

D O I：

10.1038/ncpneph1004

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The role of aldosterone in the progression of kidney dysfunction, via its actions on mineralocorticoid receptors, is increasingly recognized. The authors of this Viewpoint outline the beneficial effects that have been seen in animal and human studies of mineralocorticoid receptor blockade in various forms of kidney disease. They predict that low daily doses of the aldosterone blocker spironolactone—an inexpensive, generic medication with few and easily recognizable adverse effects—might one day become the renal equivalent of 'baby' aspirin.

引用

页码：74 / 75

页数：2

共 11 条

[1] Plasma aldosterone is independently associated with the metabolic syndrome
Bochud, Murielle
Nussberger, Jurg
Bovet, Pascal
Maillard, Marc R.
Elston, Robert C.
Paccaud, Fred
Shamlaye, Conrad
Burnier, Michel
[J]. HYPERTENSION, 2006, 48 (02) : 239 - 245
[2] Change in proteinuria after adding aldosterone Blockers to ACE inhibitors or angiotensin receptor Blockers in CKD: A systematic review
Bomback, Andrew S.
Kshirsagar, Abhijit V.
Amamoo, M. Ahinee
Klemmer, Philip J.
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (02) : 199 - 211
[3] The incidence and implications of aldosterone breakthrough
Bomback, Andrew S.
Klemmer, Philip J.
[J]. NATURE CLINICAL PRACTICE NEPHROLOGY, 2007, 3 (09): : 486 - 492
[4] Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration
de Paula, RB
da Silva, AA
Hall, JE
[J]. HYPERTENSION, 2004, 43 (01) : 41 - 47
[5] Aldosterone in chronic kidney and cardiac disease
Hostetter, TH
Ibrahim, HN
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09): : 2395 - 2401
[6] Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone
Mejia-Vilet, Juan M.
Ramirez, Victoria
Cruz, Cristino
Uribe, Norma
Gamba, Gerardo
Bobadilla, Norma A.
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 293 (01) : F78 - F86
[7] The role of aldosterone blockade in murine lupus nephritis
Monrad, Seetha U.
Killen, Paul D.
Anderson, Marc R.
Bradke, Amanda
Kaplan, Mariana J.
[J]. ARTHRITIS RESEARCH & THERAPY, 2008, 10 (01)
[8] Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors
Nagase, Miki
Yoshida, Shigetaka
Shibata, Shigeru
Nagase, Takashi
Gotoda, Takanari
Ando, Katsuyuki
Fujita, Toshiro
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (12): : 3438 - 3446
[9] Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity
Perez-Rojas, Jazmin
Blanco, Jorge A.
Cruz, Cristino
Trujillo, Joyce
Vaidya, Vishal S.
Uribe, Norma
Bonventre, Joseph V.
Gamba, Gerardo
Bobadilla, Norma A.
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 292 (01) : F131 - F139
[10] Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity
Pérez-Rojas, JM
Derive, S
Blanco, JA
Cruz, C
de la Maza, LM
Gamba, G
Bobadilla, NA
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (05) : F1020 - F1030

← 1 2 →